ClinicalTrials.gg
Not yet recruitingNCT07874256Updated Oct 14, 2026

Non-Contrast-Enhanced Breast MRI in the Evaluation of Newly Diagnosed Breast Cancer: A Pilot Study

An interventional study of Non-Contrast-Enhanced Breast MRI in Breast Cancer and Breast Cancer Detection, sponsored by Massachusetts General Hospital. Not yet recruiting. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Massachusetts General Hospital · Not applicable, Interventional, and Diagnostic

Updated Oct 14, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Study summary

This pilot study is evaluating whether breast MRI without contrast dye can provide useful information in patients who have recently been diagnosed with breast cancer. The study uses MRI techniques to look at breast tissue and the extent of cancer without an intravenous gadolinium injection and compare it to contrast enhanced MRI.

02

Conditions studied

  • Breast Cancer
  • Breast Cancer Detection

Browse trials for

03

In context

Breast Neoplasms

12,815 studies on the registry are indexed under Breast Neoplasms; 2,920 are open to participants now.

This study's planned enrollment of 20 is below the median of 72 across 9,494 interventional studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Massachusetts General Hospital is the lead sponsor of 2,582 studies on the registry; 451 are open to participants now.

Of its 221 completed or terminated interventional studies of FDA-regulated products, 168 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women aged 18 years or older.
  • Pathologically confirmed, newly diagnosed breast cancer.
  • Scheduled to undergo a clinically indicated contrast-enhanced breast MRI (CE-MRI) at Massachusetts General Hospital.
  • Able to provide verbal informed consent as approved by the IRB.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy.
  • Any contraindication to MRI, including unsafe or non-MRI-compatible implanted medical devices or metallic foreign bodies.
  • Inability to safely undergo breast MRI or remain still for the duration of the examination.
  • Inability to complete the additional approximately 5-minute NC-MRI sequence.
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Non-Contrast-Enhanced Breast MRI

    Device: Non-Contrast-Enhanced Breast MRI

Interventions

  • DeviceNon-Contrast-Enhanced Breast MRI

    A 5-minute NC-MRI sequence is the research intervention being evaluated

06

What researchers measure

Primary outcomes

  1. Feasibility of Non-Contrast-Enhanced MRI Acquisition

    Time frame: 12 months

Secondary outcomes

  1. Agreement Between NC-MRI and CE-MRI

    Time frame: 12 Months

07

Study locations

No study locations are listed for this record.

08

References and documents

Study documents

  • Protocol and statistical analysis plan · May 22, 2026

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07874256
Responsible party
Hajer Jarraya (Principal Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Oct 14, 2026
Start date
Nov 2026 (estimated)
Primary completion
Jun 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Oct 14, 2026

Study contacts

HAJER JARRAYA, MD
Contact
hjarraya@mgh.harvard.edu
617-724-9729

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion